Dopaminergic imaging in degenerative parkinsonisms, an established clinical diagnostic tool
Open Access
- 22 December 2021
- journal article
- review article
- Published by Wiley in Journal of Neurochemistry
- Vol. 164 (3) , 346-363
Abstract
Parkinson's disease (PD) and other neurodegenerative parkinsonisms are characterised by loss of striatal dopaminergic neurons. Dopamine functional deficits can be measured in vivo using positron emission tomography (PET) and single‐photon emission computed tomography (SPECT) ligands assessing either presynaptic (e.g. dopamine synthesis and storage, transporter density) or postsynaptic terminals (i.e. D2 receptors availability). Nuclear medicine imaging thus helps the clinician to separate degenerative forms of parkinsonism with other neurological conditions, e.g. essential tremor or drug‐induced parkinsonism. With the present study, we aimed at summarizing the current evidence about dopaminergic molecular imaging in the diagnostic evaluation of PD, atypical parkinsonian syndromes and dementia with Lewy bodies (DLB), as well as its potential to distinguish these conditions and to estimate disease progression. In fact, PET/SPECT methods are clinically validated and have been increasingly integrated into diagnostic guidelines (e.g. for PD and DLB). In addition, there is novel evidence on the classification properties of extrastriatal signal. Finally, dopamine imaging has an outstanding potential to detect neurodegeneration at the premotor stage, including REM‐sleep behavior disorder and olfactory loss. Therefore, inclusion of subjects at an early stage for clinical trials can largely benefit from a validated in vivo biomarker such as presynaptic dopamine pathways PET/SPECT assessment. imageKeywords
Funding Information
- Velux Stiftung (1123)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030‐159459, 320030‐169876, 320030‐185028)
This publication has 122 references indexed in Scilit:
- Pre- and Postsynaptic Dopamine SPECT in Idiopathic Parkinsonian Diseases: A Follow-Up StudyBioMed Research International, 2013
- Tau and Tauopathies2012
- Dopamine Transporter SPECT Imaging in Corticobasal SyndromePLOS ONE, 2011
- Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human BrainJAMA, 2009
- Parkinson's Disease and Residential Exposure to Maneb and Paraquat From Agricultural Applications in the Central Valley of CaliforniaAmerican Journal of Epidemiology, 2009
- Second consensus statement on the diagnosis of multiple system atrophyNeurology, 2008
- Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsyJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodiesNeuroscience Letters, 1998
- Mutation in the α-Synuclein Gene Identified in Families with Parkinson's DiseaseScience, 1997
- AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITYBrain, 1991